Quality of Life Assessment in Nonmelanoma Cervicofacial Skin Cancer

Rhee, John S.; Loberiza, Fausto R.; Matthews, Bryan; Neuburg, Marcy; Smith, Timothy L.; Burzynski, Mary

doi:10.1097/00005537-200302000-00004

Cited by 55 publications

(72 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Among its strengths is its applicability to many disease groups as well as the general population, so that it can be used to make comparisons between cancer patients and patients with other diseases as well as healthy populations. Since most studies of the HRQOL of cancer survivors lack either a non-cancer control group or broad normative data on non-cancer patients against which to compare the findings, this is a very important advantage in attempting to sort out the contribution of cancer to differences in HRQOL versus the effects of comorbidities and natural aging [3,6,15,31,41]. The SF-36 Health Survey has been used in several studies to assess HRQOL of cancer patients and has revealed different deficits in HRQOL, depending on the cancer entity, tumor stage, treatment-related side effects and late effects and progression of cancer, but also differences which are related to comorbidity, sex, age, partner status, socioeconomic status and other conditions.…”

Section: Discussionmentioning

confidence: 99%

Quality of life in patients with non-metastatic differentiated thyroid cancer under thyroxine supplementation therapy

Crevenna

Zettinig

Kéilani

et al. 2003

Supportive Care in Cancer

105

View full text Add to dashboard Cite

These findings indicate that "Vitality", "Role-physical", "Mental Health", "Role-emotional" and "Social functioning" are significantly impaired during the first year after diagnosis. Thereafter, quality of life improves correlating with the time since initial diagnosis. However, "Vitality" and "Role-emotional" remain permanently impaired in thyroid cancer patients. A multidisciplinary rehabilitation concept should include psychological support and an early start to exercise to improve physical performance of these patients leading to better HRQOL and to help them fulfill their social role earlier.

show abstract

Section: Discussionmentioning

confidence: 99%

Quality of life in patients with non-metastatic differentiated thyroid cancer under thyroxine supplementation therapy

Crevenna

Zettinig

Kéilani

et al. 2003

Supportive Care in Cancer

105

View full text Add to dashboard Cite

show abstract

“…Fewer comorbid conditions and increased use of sun-protective behaviors were associated with enhanced QOL. 17 It was revealed in the current study that basal cell carcinomas were found in 91.1% (n=51); squamous cell carcinomas were detected in 7.2% (n=4). Single location wise more lesions were located on the nose 22.1% (n=15) and forehead 17.6% (12).…”

Section: Discussionmentioning

confidence: 44%

An evaluation of quality of life of skin cancer patients after surgery using dermatology life quality index tool

Jain¹,

Jain²,

Singh

et al. 2016

Int J Res Med Sci

View full text Add to dashboard Cite

Background: Quality of life (QOL) has been identified as an important outcome in cancer researches yet the most common malignancy among humans, non-melanoma skin cancer (NMSC), but poorly studied. Aim of the study was to analyze the quality of life of non-melanoma skin cancer patients after surgery using dermatology life quality index inventory (DLQI). Methods: Retrospective cohort of patients operated for non-melanoma skin cancer in last 2 years and paid postoperative 4-month visit formed the study population. Inclusion criteria consisted of subjects operated for nonmelanoma skin cancer and paid follow up visits having sufficient physical and mental capacity. Fifty-six subjects fulfilled the selection criteria laid down thus included in this study. Study tools were records of patients, which were obtained from medical records section. If any more information was required, study subjects were contacted. Results: Out of total 56 study subjects, Basal cell carcinomas were found in 91.1% (n=51); squamous cell carcinomas were detected in 7.2% (n=4). Single location wise more lesions were located on the nose 22.1% (n=15) and forehead 17.6% (12). For most patients (75%), the lesion had not been previously treated. 58.9% subjects did not have any other associated co-morbid condition. Lower mean values were observed post-operative i.e. lower DLQI scores were recorded 4 months after surgery in our study which indicates that adverse effects were not very prominent thus preserving quality of life post operatively. Paired sample t-tests revealed a significant effect on DLQI item 1 (p=0.008), item 2 (p=0.043), and item 4 (p=0.003), with scores decreasing (improving QOL) after treatment. The change in total DLQI score demonstrated a trend toward significance, with overall QOL improving after treatment (p=0.024). Conclusions: Previously commonly employed dermatological Quality of life tools demonstrated minimal handicap at initial diagnosis and little change after treatment of nonmelanoma skin cancer. Development of disease-specific instrument is warranted to explore the disease process.

show abstract

“…Although the SCI was developed specifically for BCC and SCC patients and demonstrated impairment on the Emotional and the Appearance subscales in the validation study, in our study standardized scores (0 to 100) were all >75 [18]. This observation implicates that HRQoL impairment in our population (treated with imiquimod) is less than in patients who will have to be treated surgically, or that the SCI is only suitable for use in patients being treated surgically, since it was developed in a tertiary care Mohs surgery clinic [19]. …”

Section: Discussionmentioning

confidence: 72%

“…In the Skindex-17 this can be explained by the more generic aspect of the items in the questionnaire. The SCI however displayed good responsiveness before and after treatment in previous studies [19,20]. The only treatment assessed however was surgical treatment and the lesions were only located in the head and neck area.…”

Section: Discussionmentioning

confidence: 80%

Patient Perception of Imiquimod Treatment for Actinic Keratosis and Superficial Basal Cell Carcinoma in 202 Patients

et al. 2015

View full text Add to dashboard Cite

Objective: To document the impact on patient-reported outcomes and health-related quality of life (HRQoL) of treatment with imiquimod cream in patients with actinic keratosis (AK) and superficial basal cell carcinoma (sBCC). Methods: This open-label, multicenter study included AK and sBCC patients eligible for treatment with imiquimod 5% cream. HRQoL was measured by the Skindex-17 and the Skin Cancer Index (SCI) and treatment satisfaction by the Treatment Satisfaction Questionnaire for Medication. Results: 118 AK patients and 84 patients with sBCC were included. Low baseline HRQoL impairment was found on both questionnaires, which remained low after treatment, except for a small dip at the end of the application period. Conclusion: Imiquimod 5% cream treatment has no clinically relevant HRQoL impact in AK and sBCC patients according to the Skindex-17 and SCI. The effect of imiquimod treatment on HRQoL may be limited or these questionnaires do not fully capture relevant issues, such as fear of recurrence.

show abstract

Quality of Life Assessment in Nonmelanoma Cervicofacial Skin Cancer

Cited by 55 publications

References 21 publications

Quality of life in patients with non-metastatic differentiated thyroid cancer under thyroxine supplementation therapy

Quality of life in patients with non-metastatic differentiated thyroid cancer under thyroxine supplementation therapy

An evaluation of quality of life of skin cancer patients after surgery using dermatology life quality index tool

Patient Perception of Imiquimod Treatment for Actinic Keratosis and Superficial Basal Cell Carcinoma in 202 Patients

Contact Info

Product

Resources

About